Gallium(III) Complex Induces Immunogenic Cell Death Hallmarks for Chemoimmunotherapy.

Area of Science:

• Inorganic Chemistry
• Cancer Research
• Immunology

Background:

• Tumor metastases are a primary cause of cancer mortality.
• Chemotherapeutic agents inducing immunogenic cell death (ICD) offer potential for metastatic cancer treatment.
• Gallium (Ga(III)) complexes are explored for their therapeutic properties.

Purpose of the Study:

• To synthesize and biologically evaluate a novel Ga(III) complex with Schiff bases for cancer therapy.
• To investigate the compound's potential for combined chemotherapy and immunotherapy.
• To assess the compound's efficacy in inducing immunogenic cell death.

Main Methods:

• Chemical synthesis of the Ga(III) complex: [Ga((E)-1-((quinolin-8-ylimino)methyl)naphthalen-2-olato)2][Cl].
• In vitro cytotoxicity assays against human breast, pancreatic, and cervical cancer cell lines, and human fibroblasts.
• Mechanistic studies to identify apoptosis and ICD hallmarks (calreticulin exposure, eIF2α phosphorylation, HMGB1 release, ATP release).
• In vitro assessment using multicellular tumor spheroids of cervical cancer cell lines.

Main Results:

• The Ga(III) complex demonstrated broad cytotoxicity against tested cancer cell lines.
• The compound induced key hallmarks of ICD, including calreticulin translocation, eIF2α phosphorylation, HMGB1 migration, and ATP release.
• Successful eradication of cervical cancer multicellular tumor spheroids was achieved at micromolar concentrations.
• The study reports one of the few Ga(III) complexes capable of inducing ICD.

Conclusions:

• The novel Ga(III) complex is a potent inducer of ICD.
• This compound holds significant potential for developing new therapeutic strategies against metastatic cancers.
• Further research into Ga(III) complexes for combined chemo-immunotherapy is warranted.